These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 27619514

  • 1. Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer.
    van Poelgeest MI, Visconti VV, Aghai Z, van Ham VJ, Heusinkveld M, Zandvliet ML, Valentijn AR, Goedemans R, van der Minne CE, Verdegaal EM, Trimbos JB, van der Burg SH, Welters MJ.
    Cancer Immunol Immunother; 2016 Dec; 65(12):1451-1463. PubMed ID: 27619514
    [Abstract] [Full Text] [Related]

  • 2. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH.
    Clin Cancer Res; 2008 Jan 01; 14(1):178-87. PubMed ID: 18172269
    [Abstract] [Full Text] [Related]

  • 3. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer.
    de Vos van Steenwijk PJ, Heusinkveld M, Ramwadhdoebe TH, Löwik MJ, van der Hulst JM, Goedemans R, Piersma SJ, Kenter GG, van der Burg SH.
    Cancer Res; 2010 Apr 01; 70(7):2707-17. PubMed ID: 20233872
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels.
    Heeren AM, Rotman J, Stam AGM, Pocorni N, Gassama AA, Samuels S, Bleeker MCG, Mom CH, Zijlmans HJMAA, Kenter GG, Jordanova ES, de Gruijl TD.
    J Immunother Cancer; 2019 Feb 12; 7(1):43. PubMed ID: 30755279
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
    Santin AD, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham GP, Hermonat PL.
    Gynecol Oncol; 2001 Jun 12; 81(3):424-32. PubMed ID: 11371133
    [Abstract] [Full Text] [Related]

  • 9. Human papillomavirus 16 E6-specific CD45RA+ CCR7+ high avidity CD8+ T cells fail to control tumor growth despite interferon-gamma production in patients with cervical cancer.
    Zehbe I, Kaufmann AM, Schmidt M, Hohn H, Maeurer MJ.
    J Immunother; 2007 Jun 12; 30(5):523-32. PubMed ID: 17589293
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Naturally processed and HLA-B8-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer.
    Oerke S, Höhn H, Zehbe I, Pilch H, Schicketanz KH, Hitzler WE, Neukirch C, Freitag K, Maeurer MJ.
    Int J Cancer; 2005 May 01; 114(5):766-78. PubMed ID: 15609316
    [Abstract] [Full Text] [Related]

  • 14. The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors.
    Heusinkveld M, Welters MJ, van Poelgeest MI, van der Hulst JM, Melief CJ, Fleuren GJ, Kenter GG, van der Burg SH.
    Int J Cancer; 2011 Jan 15; 128(2):379-89. PubMed ID: 20473854
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer.
    Zheng Y, Yang Y, Wu S, Zhu Y, Tang X, Liu X.
    Bioengineered; 2017 Jul 04; 8(4):367-373. PubMed ID: 27754760
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.